

**THE ASSOCIATION OF *CYP3A4*, *CYP3A5* AND
MTHFR GENES POLYMORPHISM ON THE
EFFICACY AND SAFETY OF ATORVASTATIN
AMONG EGYPTIAN POPULATION**

MOHAMMED GAMAL MOHAMMED MASLUB

UNIVERSITI SAINS MALAYSIA

2025

**THE ASSOCIATION OF *CYP3A4*, *CYP3A5* AND
MTHFR GENES POLYMORPHISM ON THE
EFFICACY AND SAFETY OF ATORVASTATIN
AMONG EGYPTIAN POPULATION**

by

MOHAMMED GAMAL MOHAMMED MASLUB

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

March 2025

ACKNOWLEDGEMENT

First and foremost, I praise and thank Allah SWT (Alhamdulillah) for His showers of blessings and unending help throughout my research work, which enabled me to finish the research effectively and successfully.

Next, I would like to express my heartfelt gratitude to my research supervisors, Prof. Dr. Mahasen Ali Radwan, Ph.D. (Field supervisor), who provided expert guidance in the field of clinical pharmacy and is a Professor and the Head of the Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Egyptian Russian University (ERU), Cairo, Egypt; Dr. Nur Aizati Athirah Daud, Ph.D. (Main supervisor), who led the overall direction of my research and is a Senior Lecturer in the Discipline of Clinical Pharmacy at the School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM), Penang, Malaysia; and Dr. Abubakar Sha'aban, Ph.D. (Co-supervisor), who offered valuable insights from the perspective of clinical research, and is a Research Associate in the division of population medicine at Cardiff University, Cardiff, Wales, UK. Their sincerity, vision, dynamism, patience, and motivation have deeply inspired me during the research work and thesis preparation. Working and studying under their guidance was a great privilege and honor.

I am profoundly grateful to my parents, wife, children, brother, sister, and all my family members for their unwavering prayers, love, care, and sacrifices. Their support has been a constant source of strength during my research project and throughout my life.

Finally, my heartfelt thanks go to all the people who have supported me to accomplish the research work directly or indirectly.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	iv
LIST OF TABLES	xv
LIST OF FIGURES	xviii
LIST OF SYMBOLS	xix
LIST OF ABBREVIATIONS	xx
LIST OF APPENDICES	xxiii
ABSTRAK	xxv
ABSTRACT	xxvii
CHAPTER 1 INTRODUCTION	1
1.1 Background of the study	1
1.2 Problem statement & Study rationale.....	9
1.3 Research Question(s).....	12
1.3.1 What are the allele frequencies of <i>CYP3A4*1B</i> (<i>rs2740574</i> C/T), <i>CYP3A5*3</i> (<i>rs776746</i> T/C), <i>CYP3A4*22</i> (<i>rs35599367</i> G/A), and <i>MTHFR</i> (<i>rs1801133</i> G/A) among the study Egyptian population?.....	12
1.3.2 Would atorvastatin efficacy (serum lipid and lipoprotein levels) be affected by the genetic polymorphisms of these enzymes?	12
1.3.3 Would atorvastatin plasma levels be affected by the genetic polymorphisms of these enzymes?.....	12
1.3.4 Would atorvastatin safety (liver enzymes, TB, and CK levels) be affected by the genetic polymorphisms of these enzymes after atorvastatin four-week treatment?.....	12
1.3.5 Would the pharmacokinetics profile of atorvastatin be affected in carriers of the homozygous mutant genotypes of <i>CYP3A4*1B</i> (<i>rs2740574</i> C/T) and <i>CYP3A5*3</i> (<i>rs776746</i> T/C) SNPs? (The investigation will focus solely on the <i>CYP3A4*1B</i> (Al-Eitan, 2020) and <i>CYP3A5*3</i> (Mutawi et al., 2021) variants. Literature data suggest that these variants	

have a higher prevalence compared to *CYP3A4*22* (*rs35599367* G/A) (Ebid, Ismail, Lotfy, Mahmoud, & M, 2022) and *MTHFR* (*rs1801133* G/A) (El-Khawaga et al., 2024) SNPs in similar populations. Additionally, the study is constrained by the principal investigator’s personal funding, which limited the exploration of the associations between other SNPs and atorvastatin pharmacokinetics.)..... 12

1.4 Research hypotheses 13

1.4.1 The allele frequencies of *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A), and *MTHFR* (*rs1801133* G/A) among the study Egyptian population would be similar to Caucasians..... 13

1.4.2 The genetic polymorphisms of these enzymes affect serum lipid and lipoprotein levels (atorvastatin efficacy). The *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), and *CYP3A4*22* (*rs35599367* G/A) are associated with improving the lipid profile. However, the *MTHFR* (*rs1801133* G/A) is associated with worsening the lipid profile. 13

1.4.3 The genetic polymorphisms of these enzymes impact atorvastatin plasma levels. The *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), and *CYP3A4*22* (*rs35599367* G/A) are associated with high atorvastatin plasma levels. However, the *MTHFR* (*rs1801133* G/A) is associated with low atorvastatin plasma levels. 13

1.4.4 The genetic polymorphisms of these enzymes affect liver enzyme levels, TB, and CK levels after atorvastatin treatment. The *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), and *CYP3A4*22* (*rs35599367* G/A) are associated with high liver enzyme levels, TB, and CK levels. However, the *MTHFR* (*rs1801133* G/A) is associated with low liver enzyme levels, TB, and CK levels. 13

1.4.5 In carriers of the homozygous mutant genotypes of the *CYP3A4*1B* (*rs2740574* C/T) and *CYP3A5*3* (*rs776746* T/C) alleles, the pharmacokinetics profile of atorvastatin is affected..... 13

1.5 Research aim and objectives 13

1.5.1 General 13

1.5.2 Specific..... 14

1.5.2(a) Objective 1..... 14

1.5.2(b) Objective 2..... 14

1.5.2(c)	Objective 3.....	14
1.5.2(d)	Objective 4.....	14
1.5.2(e)	Objective 5.....	15
CHAPTER 2 LITERATURE REVIEW.....		16
2.1	Genetic polymorphisms that affect atorvastatin response.....	16
2.2	Worldwide allele frequencies of <i>CYP3A4*1B</i> , <i>CYP3A4*22</i> , <i>CYP3A5*3</i> , and <i>MTHFR</i> SNPs across ethnicities	17
2.3	Influence of CYP3A polymorphisms on atorvastatin efficacy	18
2.3.1	Influence of <i>CYP3A4*1B</i> polymorphism.....	18
2.3.2	Influence of <i>CYP3A4*22</i> polymorphism	19
2.3.3	Influence of <i>CYP3A5*3</i> polymorphism	20
2.4	Influence of CYP3A polymorphisms on atorvastatin safety profile	21
2.4.1	Influence of <i>CYP3A4*1B</i> polymorphism.....	21
2.4.2	Influence of <i>CYP3A4*22</i> polymorphism	21
2.4.3	Influence of <i>CYP3A5*3</i> polymorphism	22
2.5	<i>CYP3A4</i> polymorphism among Egyptians	23
2.6	<i>CYP3A5*3</i> polymorphism among Egyptians	23
2.7	Influence of <i>MTHFR</i> (<i>rs1801133</i> G/A) polymorphism	25
2.7.1	Effect of <i>MTHFR</i> (<i>rs1801133</i>) genetic polymorphisms on lipid profile.....	25
2.7.2	Association of <i>MTHFR</i> (<i>rs1801133</i>) genetic polymorphisms with CVDs.....	26
2.8	Influence of <i>CYP3A4*1B</i> , <i>CYP3A4*22</i> , <i>CYP3A5*3</i> , and <i>MTHFR</i> SNPs on atorvastatin Pharmacokinetics.....	27
CHAPTER 3 METHODOLOGY.....		30
3.1	Conceptual framework	30
3.2	Research design.....	30
3.2.1	Genotyping	32
3.2.2	Serum lipid and lipoprotein levels	32

3.2.3	Subject's criteria.....	32
3.2.3(a)	Inclusion Criteria	33
3.2.3(b)	Exclusion Criteria	34
3.2.4	Atorvastatin plasma concentration	36
3.2.5	Atorvastatin safety profile	37
3.2.6	Atorvastatin pharmacokinetics	38
3.3	Study site	40
3.4	Study population	40
3.4.1	Reference population.....	40
3.4.1(a)	Target population.....	40
3.5	Sample size estimation	41
3.6	Sampling method and subject recruitment	43
3.6.1	Sampling method.....	43
3.6.2	Subject recruitment	43
3.7	Research tools and procedure for the determination of atorvastatin plasma concentration	45
3.7.1	Chemicals and materials.....	46
3.7.2	Chromatographic conditions	46
3.7.3	Mass spectrometry conditions	47
3.7.4	Preparation of calibration standards and quality control samples	48
3.7.5	Plasma sample preparation.....	48
3.7.6	Method validation	49
3.7.6(a)	Selectivity and specificity	49
3.7.6(b)	Sensitivity and carryover	49
3.7.6(c)	Linearity.....	50
3.7.6(d)	Accuracy and precision.....	50
3.7.6(e)	Extraction recovery.....	50

3.7.6(f)	Matrix effect	51
3.7.6(g)	Stability.....	51
3.8	Research tools and procedure for genotyping of the SNPs	51
3.8.1	Genomic DNA extraction.....	52
3.8.1(a)	Materials and reagents used.....	52
3.8.1(b)	Procedure	52
3.8.2	Amplification and real-time PCR allelic discrimination assays.....	54
3.8.2(a)	Principle.....	54
3.8.2(b)	Materials and reagents used.....	54
3.8.2(c)	Procedure	56
3.9	Operational definition	58
3.9.1	A SNP is a genomic variant at a definite single base location in the DNA (Institute, 2022).	58
3.9.2	Regarding the CYP3A4*1B SNP, the (C/C) genotype is the wild-type genotype, and the (T/T) is the mutant homozygous genotype.	58
3.9.3	About the CYP3A5*3 SNP, the (T/T) genotype is the wild-type genotype, and the (C/C) is the mutant homozygous genotype.	58
3.9.4	Relating to the CYP3A4*22 SNP, the (G/G) genotype is the wild-type genotype, and the (A/A) is the mutant homozygous genotype.	58
3.9.5	Concerning the MTHFR SNP, the (G/G) genotype is the wild-type genotype, and the (A/A) is the mutant homozygous genotype.	58
3.9.6	Dyslipidemia is defined as LDL-C \geq 130 mg/dl, TC \geq 200 mg/dl, TG \geq 150 mg/dl, or HDL-C $<$ 50 (for women), and HDL-C $<$ 40 mg/dl (for men) (Hedayatnia et al., 2020).....	58
3.9.7	High-intensity statins are doses of statins that can decrease LDL-C by at least 50%. These statins include atorvastatin 40 mg (Rahhal et al., 2022).....	58
3.9.8	For evaluating atorvastatin efficacy, the TC, LDL-C, HDL-C, TG, and atorvastatin plasma levels can be compared pre- and post-atorvastatin treatment in the carriers of the variant alleles	

	of the studied genes with the same levels in the carriers of the wild genotypes.....	58
3.9.9	To assess the safety of atorvastatin.	58
3.9.10	Reference ranges for serum ALT: 0–48 U/L, serum AST: 0–40 U/L, serum TB: 0–1.0 mg/dL, and serum CK: up to 250 U/L (Punukollu et al., 2004; VanWagner & Green, 2015).	58
3.9.11	Drug-induced liver injury in this study is defined according to Hy's Law, as outlined by the FDA, where TB exceeds 2 mg/dL and either AST or ALT exceeds three times the ULN. It is important to note that all study participants had normal liver function at baseline, with no pre-existing liver disease or impaired liver function (Fettiplace et al., 2024; Fontana et al., 2023; U.S.FDA, 2009).	58
3.9.12	Myopathy is characterized by muscle pain or weakness without a clear cause, along with serum CK levels exceeding 10 times the ULN (Cheeley et al., 2022).....	58
3.9.13	Rhabdomyolysis, a more severe muscle-related condition, is identified by CK levels typically surpassing 40 times the ULN (Cheeley et al., 2022).	59
3.9.14	The pharmacokinetic parameters of atorvastatin observed in this study can be interpreted by comparing them with those reported in other studies involving healthy Egyptian volunteers without CYP3A4 and CYP3A5 genetic polymorphisms, as well as with data from other ethnic populations. These parameters include the AUC, $t_{1/2}$, k, CL/F, and CL.	59
3.10	Data collection method.....	59
3.10.1	Data collection sheet:	59
3.10.2	Blood sampling:	59
3.11	Study flowchart	60
3.12	Study variables	61
3.13	Data analysis	61
3.13.1	Statistical analysis for the first objective.....	62
3.13.2	Statistical analysis for the second objective.....	62
3.13.3	Statistical analysis for the third objective	62
3.13.4	Statistical analysis for the fourth objective	62

3.13.5	Statistical analysis for the fifth objective	63
3.14	Ethical considerations	65
3.14.1	Privacy and confidentiality.....	65
3.14.2	Ethical review boards approval	65
CHAPTER 4	RESULTS.....	68
4.1	Subjects' demographics.....	68
4.2	Assessment of Normality	69
4.3	Statistical Techniques: ANCOVA and Pearson Correlation Analysis.....	70
4.3.1	Pre-atorvastatin treatment	70
4.3.2	Post-atorvastatin treatment.....	71
4.4	Allele frequencies of <i>CYP3A4*1B</i> (<i>rs2740574</i> C/T), <i>CYP3A5*3</i> (<i>rs776746</i> T/C), <i>CYP3A4*22</i> (<i>rs35599367</i> G/A), and <i>MTHFR</i> (<i>rs1801133</i> G/A) alleles among the study Egyptian population.....	71
4.4.1	<i>CYP3A4*1B</i> allele frequency	71
4.4.2	<i>CYP3A5*3</i> allele frequency	74
4.4.3	<i>CYP3A4*22</i> (<i>rs35599367</i> G/A) allele frequency.....	74
4.4.4	<i>MTHFR</i> (<i>rs1801133</i> G/A) allele frequency	74
4.4.5	Genotypes and prediction statistical analysis.....	75
4.4.6	Hardy-Weinberg Equilibrium Analysis	76
4.5	Effect of genetic polymorphisms on atorvastatin efficacy.....	76
4.5.1	<i>CYP3A4*1B</i> (<i>rs2740574</i> C/T) and atorvastatin efficacy	76
4.5.2	<i>CYP3A5*3</i> (<i>rs776746</i> T/C) and atorvastatin efficacy.....	80
4.5.3	<i>CYP3A4*22</i> (<i>rs35599367</i> G/A) and atorvastatin efficacy.....	82
4.5.4	<i>MTHFR</i> (<i>rs1801133</i> G/A) and atorvastatin efficacy.....	84
4.5.4(a)	Effect on baseline serum lipid/lipoprotein.....	84
4.5.4(b)	Effect on post-treatment serum lipid/lipoprotein.....	85
4.6	Effect of genetic polymorphisms on atorvastatin safety	88
4.6.1	<i>CYP3A4*1B</i> (<i>rs2740574</i> C/T) and atorvastatin safety.....	88

4.6.1(a)	Serum ALT/AST	88
4.6.1(b)	Serum TB.....	88
4.6.1(c)	Serum CK	89
4.6.2	<i>CYP3A5</i> *3 (<i>rs776746</i> T/C) and atorvastatin safety	95
4.6.2(a)	Liver enzymes and serum TB	95
4.6.2(b)	Serum CK	95
4.6.3	<i>CYP3A4</i> *22 (<i>rs35599367</i> G/A) and atorvastatin safety	97
4.6.3(a)	Serum aminotransferases and CK.....	97
4.6.3(b)	Serum TB.....	97
4.6.4	<i>MTHFR</i> (<i>rs1801133</i> G/A) and atorvastatin safety.....	99
4.6.4(a)	Serum ALT	99
4.6.4(b)	Post-treatment serum TB	100
4.6.4(c)	<i>MTHFR</i> SNP genotypes and serum AST, TB, and CK.....	100
4.7	Atorvastatin plasma level	103
4.7.1	Chromatography and selectivity.....	103
4.7.2	LC-MS/MS validation.....	104
4.7.2(a)	Linearity: The AUP ratio of atorvastatin to the IS in the plasma showed excellent linear associations ($r=0.998$) for the 1–1000 ng/mL concentration range. With a mean correlation of 0.998 ± 0.001 , the AUP ratios (y) against atorvastatin concentrations (x) had a mean linear regression equation of $Y = - 0.03517 + 0.01784X$ (Figure 4.3).....	104
4.7.2(b)	Sensitivity and carryover: This assay's lower limit of quantification (LLOQ) in human plasma was one ng/mL, and the ultrafiltrate's corresponding RSD was 9.6%. At a signal-to-noise ratio (S/N) > 3, the limit of detection (LOD) was 0.3 ng/mL (Figure 4.4). No indication of sample carryover from one run to the next was found.	104
4.7.2(c)	Accuracy and precision: The reproducibility of the assay was evaluated by comparing the linear regressions of three standard plots prepared on	

	three different days over three months. For each of the three slopes, the RSD was 11.7%, and the mean correlation coefficient was >0.996. The data ANOVA revealed no significant difference ($p > 0.05$) in the calibration curves' slopes or the intra- and inter-day measurements. The results validated the assay method's reproducibility. 10% was established as the highest allowable limit for accuracy and precision. The precision (RSD) within and between runs was less than 10%. For atorvastatin, the accuracy as a relative error was 4.8 ± 1.7	105
4.7.2(d)	Extraction recovery: Atorvastatin recovery was $89.8 \pm 8.0\%$ on average, with an RSD of $\leq 10.5\%$. Over the range of concentrations examined, there was no discernible variation in the current assay's extraction effectiveness.	106
4.7.2(e)	Matrix effect: The matrix effect was assessed by comparing spiked samples (post-processing) with spiked injection solvents; it showed a <10% difference.	106
4.7.2(f)	Stability: Processed samples kept in the autosampler for 24 hours at ten °C showed stability for both IS and atorvastatin, with mean estimated values falling between 8.7% and 10% of the nominal concentration.	106
4.7.3	Clinical applications on patients' plasma samples.....	106
4.7.4	<i>CYP3A4*1B</i> genotypes and atorvastatin plasma levels	106
4.7.5	<i>CYP3A5*3</i> genotypes and atorvastatin plasma levels.....	108
4.7.6	<i>CYP3A4*22</i> genotypes and atorvastatin plasma levels.....	109
4.7.7	<i>MTHFR</i> SNP genotypes and atorvastatin plasma levels.....	109
4.7.8	ROC curves	110
4.8	Clinical pharmacokinetics of atorvastatin	111
CHAPTER 5 DISCUSSION OF THE MAIN FINDINGS		116
5.1	Allele frequencies among the study Egyptian participants	116
5.1.1	<i>CYP3A4*1B</i> (rs2740574 C/T) SNP	116
5.1.2	<i>CYP3A5*3</i> (rs776746) SNP	117

5.1.3	CYP3A4*22 (rs35599367 G/A) SNP	117
5.1.4	MTHFR (rs1801133 G/A) SNP	118
5.2	Effect of genetic polymorphisms on atorvastatin efficacy	118
5.2.1	<i>CYP3A4*1B</i> effect on atorvastatin efficacy	118
5.2.2	<i>CYP3A5*3</i> effect on atorvastatin efficacy	119
5.2.3	<i>CYP3A4*22</i> effect on atorvastatin efficacy	120
5.2.4	<i>MTHFR</i> SNP effect on atorvastatin efficacy.....	122
5.3	Effect of genetic polymorphisms on atorvastatin safety	123
5.3.1	<i>CYP3A4*1B</i> effect on atorvastatin safety	124
5.3.2	<i>CYP3A5*3</i> effect on atorvastatin safety.....	126
5.3.3	<i>CYP3A4*22</i> effect on atorvastatin safety.....	127
5.3.4	<i>MTHFR</i> SNP effect on atorvastatin safety.....	128
5.4	Atorvastatin plasma level	130
5.4.1	Genotype (T/T) of <i>CYP3A4*1B</i> (rs2740574 C/T) variant.....	130
5.4.2	Genotype (C/C) of <i>CYP3A5*3</i> (rs776746 T/C) variant.....	130
5.4.3	ROC curves	131
5.4.4	<i>CYP3A4*22</i> genotypes.....	133
5.4.5	<i>MTHFR</i> SNP genotypes	133
5.5	Atorvastatin pharmacokinetics	134
5.5.1	Comparison to Arab population (Egyptians and Jordanians).....	134
5.5.2	Comparison to Caucasian population.....	135
5.5.3	Comparison to Asian populations	137
CHAPTER 6 CONCLUSION AND FUTURE RECOMMENDATIONS....		139
6.1	Conclusion.....	139
6.2	Limitations of the study.....	141
6.3	Recommendations for Future Research	142

REFERENCES..... 144

APPENDICES

LIST OF PUBLICATIONS

LIST OF TABLES

		Page
Table 2.1	Studies reporting influences of <i>CYP3A/ MTHFR</i> genetic polymorphisms	29
Table 3.1	Context sequence for each SNP	56
Table 3.2	PCR amplification of <i>CYP3A4</i> , <i>CYP3A5</i> , and <i>MTHFR</i> promoter regions using sequence-specific primers and Applied Biosystems-recommended thermal cycling conditions	57
Table 4.1	Demographic and Clinical Characteristics of the Study Subjects (n = 100).....	69
Table 4.2	Allelic and genotype frequencies and percentages of <i>CYP3A4*1B</i> (<i>rs2740574 C/T</i>), <i>CYP3A5*3</i> (<i>rs776746 T/C</i>), <i>CYP3A4*22</i> (<i>rs35599367 G/A</i>) and <i>MTHFR</i> (<i>rs1801133 G/A</i>) polymorphisms ...	73
Table 4.3	Logistic regression analysis of <i>CYP3A4*1B</i> (<i>rs2740574 C/T</i>) homozygous mutant and heterozygous genotypes on <i>CYP3A5*3</i> (<i>rs776746 T/C</i>) homozygous mutant and heterozygous genotypes ...	75
Table 4.4	Hardy-Weinberg Equilibrium Analysis of Studied SNPs.....	76
Table 4.5	Association between <i>CYP3A4*1B</i> (<i>rs2740574 C/T</i>) genetic polymorphisms, serum lipid/lipoprotein levels, and other clinical parameters pre and post-atorvastatin four-week treatment	78
Table 4.6	Association between <i>CYP3A5*3</i> (<i>rs776746 T/C</i>) genetic polymorphisms, serum lipid/lipoprotein levels, and other clinical parameters pre and post-atorvastatin four-week treatment	81
Table 4.7	Association between <i>CYP3A4*22</i> (<i>rs35599367 G/A</i>) genetic variations, serum lipid/lipoprotein levels, and other clinical parameters before and after atorvastatin one-month therapy	83

Table 4.8	Association between <i>MTHFR</i> (<i>rs1801133</i> G/A) genetic variations, serum lipid/lipoprotein levels, and other clinical parameters before and after atorvastatin one-month therapy.....	86
Table 4.9	Relationships between genotypes of <i>CYP3A4*1B</i> (<i>rs2740574</i> C/T) and <i>CYP3A5*3</i> (<i>rs776746</i> T/C) and investigated parameters (atorvastatin plasma levels and change in CK levels) among the study subjects (n = 100)	90
Table 4.10	Association of <i>CYP3A4*1B</i> (<i>rs2740574</i> C/T) genetic polymorphisms with serum ALT, AST, TB, and CK levels before and after four weeks of atorvastatin therapy	92
Table 4.11	Genotype-based variations in serum total bilirubin (TB) levels before and after one month of atorvastatin therapy	94
Table 4.12	Association of <i>CYP3A5*3</i> (<i>rs776746</i> T/C) genetic polymorphisms with serum ALT, AST, TB, and CK levels before and after four weeks of atorvastatin therapy	96
Table 4.13	Association between <i>CYP3A4*22</i> (<i>rs35599367</i> G/A) genetic variations and serum ALT, AST, TB, and CK pre and post-atorvastatin four-week treatment	98
Table 4.14	Association between <i>MTHFR</i> (<i>rs1801133</i> G/A) genetic variations and serum ALT, AST, TB, and CK pre and post-atorvastatin four-week treatment	101
Table 4.15	Significant correlations between <i>CYP3A4*1B</i> (<i>rs2740574</i> C/T) and <i>CYP3A5*3</i> (<i>rs776746</i> T/C) genotypes and various investigated parameters among the study participants (n = 100).....	108
Table 4.16	Logistic regression analysis of <i>CYP3A4*1B</i> (<i>rs2740574</i> C/T) and <i>CYP3A5*3</i> (<i>rs776746</i> T/C) homozygous mutant genotypes on atorvastatin plasma levels	108
Table 4.17	Predictive performance of atorvastatin plasma concentration in the study subjects (n = 100)	111
Table 4.18	Comparison between the pharmacokinetic parameters of the carriers of the genotype (T/T) of the variant <i>CYP3A4*1B</i>	

(*rs2740574 C/T*) and the genotype (C/C) of the variant
*CYP3A5*3 (rs776746 T/C)* with the pharmacokinetic parameters
reported in other studies 114

LIST OF FIGURES

	Page
Figure 1.1	CYP3A4 mainly metabolizes atorvastatin through major pathways and minor pathways via CYP3A5 and CYP2D6.8
Figure 3.1	Diagrammatic illustration of the study framework.30
Figure 3.2	Research methodology flow chart.....39
Figure 3.3	A sequential graphical representation of the required steps for this study and thesis production.....60
Figure 4.1	Graphical representations for statistical regression analysis.....91
Figure 4.2	The multi-reaction monitoring (MRM) transitions of atorvastatin and rosuvastatin (IS).103
Figure 4.3	Scatter plot depicting the area under the peak (AUP) ratio of atorvastatin to the internal standard (IS) across the 1–1000 ng/mL concentration range, showing observed data points and the linear fit.104
Figure 4.4	A bar chart comparing the lower limit of quantification (LLOQ) (1.0 ng/mL) with the limit of detection (LOD) (0.3 ng/mL) of atorvastatin105
Figure 4.5	Receiver operating characteristic (ROC) curves.....111
Figure 4.6	The plasma concentration-time profile113

LIST OF SYMBOLS

a	The intercept
b	The slope
C	Plasma concentration
D	Dose
F	Oral bioavailability
J	Youden index
k	Elimination rate constant
k _a	Absorption rate constant
K _e	elimination rate constant
T	Dosing interval (hours)
t _{1/2}	The terminal plasma half-life
V _d	Volume of distribution
x	The concentration of atorvastatin
*	Statistically significant

LIST OF ABBREVIATIONS

ACC	The American College of Cardiology
AE buffer	Elution buffer
AHA	The American Heart Association
AL buffer	Lysis buffer
ALT	Alanine aminotransferase
ANCOVA	Analysis of Covariance
ANOVA	Analysis of variance
ASCVD	Atherosclerotic cardiovascular disease
AST	Aspartate aminotransferase
ATV	Atorvastatin
AUC	Area under the concentration-time curve
$AUC_{(0-\infty)}$	Area under the plasma concentration-time curve from time zero to infinity
$AUC_{(0-\tau)}$	Area under each drug concentration-time curve from dosing to the end of the dosing interval ($\tau = 24$ h)
AUROC	Area under the receiver operating characteristic curve
AUP	Area under the peak
AW1 buffer, AW2 buffer	Washing buffers
β	Regression Coefficient
BMI	Body mass index
BSA	Bovine serum albumin
CAD	Coronary artery disease
CE	Collision energy
CHD	Coronary heart disease
CHO	Cholesterol
95% CI	95% Confidence interval
CK	Creatine kinase
CL	Drug Clearance
CL/F	Apparent oral clearance
C _{max}	Maximum plasma concentration
CML	Chronic myeloid leukemia
CPIC	Clinical Pharmacogenetics Implementation Consortium

CV	Cardiovascular
CV%	Coefficient of variation
CVDs	Cardiovascular diseases
CXP	Collision cell exit potential
CYPs	Cytochromes P450 enzymes
DP	Declustering potential
DRESS	Drug rash with eosinophilia and systemic symptom
EP	Entrance potential
ESI	Electrospray ionization
FDA	US Food and Drug Administration
FH	Familial hypercholesterolemia
FLD	Fatty liver disease
GM	Geometric mean
HbA1c	Glycated hemoglobin
Hcy	Homocysteine
HDL-C	High-density lipoprotein cholesterol
HMG-CoA	Hydroxymethylglutaryl-CoA
HMOX1	Heme oxygenase-1 gene
HQC	Higher quality control
HWE	Hardy-Weinberg Equilibrium
IQR	Interquartile range
IS	Internal standard
LDL-C	low-density lipoprotein cholesterol
LLOQ	Lower limit of quantitation
LOD	Limit of detection
LQC	Lower quality control
MGB	Minor groove binder
Min – Max	Minimum value - Maximum value
MLR	Multivariate regression
MQC	Middle quality control
MRM	Multi-reaction monitoring
MTHFR	Methylenetetrahydrofolate reductase
MVA	Mevalonate
NA	Not applicable

NFQ	Non-fluorescent quencher
NR	Not reported
OATP	Organic anion transporter polypeptides
OR	Odds ratio
PAD	Peripheral artery disease
PASS	Power Analysis and Sample Size Software
POR*28	P450 oxidoreductase *28
QC	Quality control
r	Correlation coefficient
R ²	Coefficient of determination
ROC	Receiver operating characteristic curve
ROX	Carboxy-X-rhodamine
RSD	Relative standard deviation
RT-PCR	Real-time quantitative polymerase chain reaction
SAM	S-adenosylmethionine
SD	Standard deviation
SEM	Standard error of the mean
SLCO	Solute carrier organic anion 'superfamily of transporters'
SNP	Single-nucleotide polymorphism
S/N	Signal-to-noise ratio
SPSS	Statistical Package for Social Science (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp)
SRM	Selected reaction monitoring
TB	Total bilirubin
TC	Total cholesterol
TG	Triglyceride
TIA	Transient ischemic attack
T _m	Melting temperature
Tris-HCl	Tris(hydroxymethyl)aminomethane
TSH	Thyroid stimulating hormone
ULN	Upper limit of normal
UP	Ultra-pure
USPSTF	United States Preventive Services Task Force
UTIs	Urinary tract infections

LIST OF APPENDICES

- Appendix A DATA COLLECTION SHEET
- Appendix B APPROVAL LETTER FROM THE SCIENTIFIC RESEARCH ETHICS COMMITTEE AT THE FACULTY OF PHARMACY, EGYPTIAN RUSSIAN UNIVERSITY (ERU), CAIRO, EGYPT (OCTOBER 2021) "THE STUDY PROTOCOL FOR PHASE I"
- Appendix C REAPPROVAL LETTER FROM THE SCIENTIFIC RESEARCH ETHICS COMMITTEE AT THE FACULTY OF PHARMACY, EGYPTIAN RUSSIAN UNIVERSITY (ERU), CAIRO, EGYPT, AFTER SIGNIFICANT AMENDMENTS TO THE STUDY PROTOCOL (MAY 2022) "THE STUDY PROTOCOL FOR PHASE I"
- Appendix D APPROVAL LETTER FROM BADR HOSPITAL RESEARCH ETHICS COMMITTEE, CAIRO, EGYPT, IN OCTOBER 2022 (IN THE FOLLOWING TWO PAGES) "THE STUDY PROTOCOL FOR PHASE I"
- Appendix E APPROVAL LETTER FROM JAWATANKUASA ETIKA PENYELIDIKAN (MANUSIA), JEPeM, UNIVERSITI SAINS MALAYSIA (USM), PENANG, MALAYSIA, IN FEBRUARY 2023 (IN THE FOLLOWING FOUR PAGES) "THE STUDY PROTOCOL FOR PHASE I"
- Appendix F APPROVAL LETTER FROM THE SCIENTIFIC RESEARCH ETHICS COMMITTEE AT THE FACULTY OF PHARMACY, EGYPTIAN RUSSIAN UNIVERSITY (ERU), CAIRO, EGYPT IN MARCH 2023 "THE STUDY PROTOCOL FOR PHASE II"
- Appendix G APPROVAL LETTER FROM JAWATANKUASA ETIKA PENYELIDIKAN (MANUSIA), JEPeM, UNIVERSITI SAINS MALAYSIA (USM), PENANG, MALAYSIA, IN March 2024 FOR THE PROPOSED AMENDMENTS IN THE STUDY ENTITLED "INVESTIGATING *CYP3A4*1B* AND *CYP3A5*3* GENETIC POLYMORPHISMS AMONG EGYPTIANS AND THEIR EFFECTS ON ATORVASTATIN EFFICACY AND SAFETY" [USM/JEPEM/22090641] (IN THE FOLLOWING three PAGES) "THE STUDY PROTOCOL FOR PHASE II"
- Appendix H APPROVAL LETTER FROM JAWATANKUASA ETIKA PENYELIDIKAN (MANUSIA), JEPeM, UNIVERSITI SAINS MALAYSIA (USM), PENANG, MALAYSIA, IN MARCH 2024 FOR THE EXTENSION OF APPROVAL (COMMENCING FROM 17th. FEBRUARY 2024 TO 16th. FEBRUARY 2025) (IN THE FOLLOWING THREE PAGES)

Appendix I	APPROVAL LETTER FOR THE CHANGE OF THE THESIS TITLE
Appendix J	PRE-VIVA CERTIFICATE
Appendix k	TURNITIN - ORIGINALITY REPORT

**HUBUNGKAIT POLIMORFISME GEN CYP3A4, CYP3A5, DAN MTHFR
KE ATAS KEBERKESANAN DAN KESELAMATAN ATORVASTATIN
DALAM KALANGAN POPULASI MESIR**

ABSTRAK

Dislipidemia meningkatkan risiko penyakit kardiovaskular (CVD) dalam kalangan rakyat Mesir. Penyesuaian rawatan atorvastatin berdasarkan genotip dapat meningkatkan keberkesanan dan mengurangkan kesan sampingan, sekali gus menyokong usaha Projek Genom Mesir dalam meningkatkan hasil kesihatan. Kajian terdahulu tidak dapat membuktikan secara konklusif tentang hubungkait di antara tindak balas atorvastatin dengan polimorfisme genetik *CYP3A4* dan *CYP3A5*. Penyelidikan lanjut diperlukan untuk mengesahkan variasi gen *MTHFR* sebagai indikator kepada tindakbalas terhadap atorvastatin. Tiada kajian terdahulu mengenai kesan polimorfisme genetik terhadap atorvastatin dijalankan dalam kalangan penduduk Mesir. Justeru, kajian ini bertujuan untuk menyiasat kesan polimorfisme *CYP3A4*1B* (*rs2740574* C/T), *CYP3A4*22* (*rs35599367* G/A), *CYP3A5*3* (*rs776746* T/C), dan *MTHFR* (*rs1801133* G/A) terhadap rawatan atorvastatin dalam kalangan penduduk Mesir. Dalam kajian kohort prospektif ini, 100 subjek telah digenotipkan untuk alel ini. Semua subjek disaring untuk profil serum lipid, enzim hati, jumlah bilirubin dan Kreatin kinase sebelum dan selepas 4 minggu rawatan dengan atorvastatin 40 mg. Paras plasma atorvastatin dinilai 15 jam selepas dos terakhir pada setiap subjek. Farmakokinetik atorvastatin dinilai pada lima metabolizer yang lemah untuk *CYP3A4* dan *CYP3A5* yang membawa genotip *CYP3A4*1B* (T/T) dan *CYP3A5*3* (C/C). Frekuensi alel *CYP3A4*1B*, *CYP3A4*22*,

*CYP3A5*3*, dan *MTHFR* adalah masing-masing 86%, 3%, 83%, dan 30.5%. Genotip *CYP3A4*1B* (T/T), *CYP3A4*22* (G/A), dan *CYP3A5*3* (C/C) menunjukkan peningkatan yang signifikan pada serum trigliserida (TG) ($p < 0.05$). Selepas rawatan, pembawa genotip *MTHFR* (A/A) mempunyai jumlah kolesterol (TC) dan kolesterol lipoprotein ketumpatan tinggi (HDL-C) yang lebih rendah berbanding genotip (G/A) dan (G/G) ($p < 0.05$). Selepas rawatan atorvastatin, berlaku peningkatan secara signifikan bagi paras bilirubin pada genotip tertentu seperti genotip *CYP3A4*1B* (T/T), *CYP3A4*22* (G/G), *CYP3A5*3* (C/C), dan *MTHFR* (A/A) ($P < 0.001$). Paras plasma atorvastatin adalah lebih tinggi bagi pembawa genotip *CYP3A4*1B* (T/T) ($p < 0.05$) dan *CYP3A5*3* (C/C) ($p < 0.001$). Ujian regresi linear menunjukkan bahawa pembawa genotip ini lebih cenderung untuk mengalami peningkatan paras plasma atorvastatin (ng/ml). Pekali regresi β adalah 4.22 dan 4.79 pada genotip *CYP3A4*1B* (T/T) dan *CYP3A5*3* (C/C) ($P < 0.001$). Genotip *CYP3A4*22* ((G/G) dan (G/A)) dan tiga genotip *MTHFR* tidak menunjukkan perkaitan signifikan dengan kepekatan plasma atorvastatin dalam kalangan subjek. Alel *CYP3A4*1B* dan *CYP3A5*3* memberi kesan secara signifikan pada farmakokinetik atorvastatin. Dapatan ini boleh membantu pakar perubatan untuk memahami kesan genetik pada tindak balas atorvastatin di kalangan pesakit di Mesir.

**THE ASSOCIATION OF CYP3A4, CYP3A5 AND MTHFR GENES
POLYMORPHISM ON THE EFFICACY AND SAFETY OF
ATORVASTATIN AMONG EGYPTIAN POPULATION**

ABSTRACT

Dyslipidemia raises cardiovascular diseases (CVDs) risk in Egyptians. Tailoring atorvastatin treatment based on genotype can enhance efficacy and reduce adverse effects, contributing to the Egyptian Genome project's efforts to improve health outcomes. Previous studies have not provided conclusive evidence regarding the association between response to atorvastatin and *CYP3A4* and *CYP3A5* genetic polymorphisms. Further research is necessary to confirm the *MTHFR* gene variation as a predictive biomarker for responsiveness to atorvastatin. The effects of genetic polymorphisms on atorvastatin therapy were not previously studied among the Egyptians. This research aimed to investigate the effects of *CYP3A4*1B* (*rs2740574* C/T), *CYP3A4*22* (*rs35599367* G/A), *CYP3A5*3* (*rs776746* T/C), and *MTHFR* (*rs1801133* G/A) polymorphisms on atorvastatin treatment in Egyptians. In this prospective cohort study, 100 subjects were genotyped for these alleles. All participants were screened for serum lipid profiles, liver enzymes, total bilirubin (TB), and creatine kinase (CK) before and after a four-week therapy with 40 mg of atorvastatin. Atorvastatin plasma levels were assessed 15 hours after the last dose for each patient. Atorvastatin pharmacokinetics was evaluated in five poor metabolizers for *CYP3A4* and *CYP3A5* who carried the *CYP3A4*1B* (T/T) and *CYP3A5*3* (C/C) genotypes. *CYP3A4*1B*, *CYP3A4*22*, *CYP3A5*3*, and *MTHFR* allele frequencies were 86%, 3%, 83%, and 30.5% respectively. *CYP3A4*1B* (T/T), *CYP3A4*22* (G/A), and *CYP3A5*3* (C/C) genotypes revealed significant

improvement in serum triglyceride (TG) ($p < 0.05$). *MTHFR* SNP (A/A) genotype carriers had lower post-treatment total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) compared to (G/A) and (G/G) genotypes, respectively ($p < 0.05$). Atorvastatin significantly increased the post-treatment TB levels in particular genotypes such as the *CYP3A4*1B* (T/T) genotype, the *CYP3A4*22* (G/G) genotype, the *CYP3A5*3* (C/C) genotype, and the *MTHFR* SNP (A/A) genotype ($P < 0.001$). Atorvastatin plasma levels were higher in *CYP3A4*1B* (T/T) ($p < 0.05$) and *CYP3A5*3* (C/C) ($p < 0.001$) genotype carriers. Simple linear regression revealed that carrying these genotypes increased atorvastatin plasma levels in (ng/ml). The regression coefficients β were 4.22 and 4.79 in the case of the *CYP3A4*1B* (T/T) genotype and *CYP3A5*3* (C/C) genotype, respectively ($P < 0.001$). The *CYP3A4*22* ((G/G) and (G/A)) genotypes and the three *MTHFR* SNP genotypes did not show significant associations with the plasma atorvastatin concentrations among the subjects. *CYP3A4*1B* and *CYP3A5*3* alleles significantly affected atorvastatin pharmacokinetics. These findings can help clinicians understand the genetic influences on atorvastatin response in Egyptian patients.

CHAPTER 1

INTRODUCTION

1.1 Background of the study

Pharmacogenetics is a valuable approach that predicts sub-therapeutic responses to pharmacologic treatments and increased risks of adverse drug reactions (Wake, Ilbawi, Dunnenberger, & Hulick, 2019). Genetic variations occurring naturally in human genes lead to differences in responses to drug therapy (Hauser et al., 2018). Pharmacogenetics has a noteworthy role in assessing the influence of genetic mutations on responses to pharmacologic treatments (Gray, Adhikary, & Janicki, 2018). Many clinically used medications are metabolized by Cytochromes P450 enzymes (CYPs) (Y. Song et al., 2021). Any noticeable decrease or increase in the metabolite levels could occur due to genetic polymorphisms of these vital enzymes, resulting in changes in drug therapeutic outcomes (Chowdhury et al., 2021; Y. Zhang et al., 2024). The metabolism of drugs is considered an essential process that determines responses to medications, adverse effects, and pharmacokinetics (Nakajima, 2017).

The CYP450 enzymes are essential for human health, contributing significantly to xenobiotic metabolism and drug response (Hossam Abdelmonem et al., 2024). In addition to metabolizing medications, they also play a crucial role in the breakdown of endogenous compounds, including bile acids and steroid hormones. Furthermore, these enzymes are actively involved in the biosynthesis of both bile acids and steroids (Hossam Abdelmonem et al., 2024). The CYPs or cytochrome P450 enzyme family is a vast group of heme-containing proteins (Talevi & Bellera, 2021). These enzymes possess the organic cofactor heme, which serves as an essential prosthetic group for their catalytic function. The name of this

superfamily originates from their distinct spectrophotometric absorption peak at 450 nm when exposed to reduced carbon monoxide (Talevi & Bellera, 2021). Moreover, CYPs are more than 50 different enzymes, but the isoenzymes classified under the CYP1, CYP2, and CYP3 families are essential for the metabolism of nearly 80% of the clinically used medications (M. Zhao et al., 2021). CYPs are primarily expressed in the liver. In addition, they are present in the kidneys, placenta, skin, and gastrointestinal tract. CYPs play a role in over 90% of the reported enzymatic reactions (M. Zhao et al., 2021).

A definite gene encodes for every CYP. Each person inherits only one genetic allele from each parent. Alleles are considered to be "wild type" or "variant". The wild form presents frequently in the general population. A normal metabolizer is called an "extensive metabolizer," which has received two copies of the wild alleles. Genetic variations occur when a genetic variant substitutes only one or both wild alleles. Genetic variants usually encode specific CYPs with no function, reduced function, (Hossam Abdelmonem et al., 2024) or increased function (Lee et al., 2021; Marin et al., 2020). People who carry two copies of genetic variants with little to no enzyme activity are called "poor metabolizers" (Hossam Abdelmonem et al., 2024). People who inherit one allele of each kind exhibit lower enzymatic activity and are categorized as "intermediate metabolizers" (Hossam Abdelmonem et al., 2024). Individuals known as "ultra-rapid metabolizers" carry multiple copies of the wild genetic form (Hossam Abdelmonem et al., 2024) or two copies of the variant that enhances enzyme activity (Lee et al., 2021). Carriers of one allele for increased enzyme activity and one normal-function allele are referred to as "rapid metabolizers" (Lee et al., 2021). Precision medicine strategies necessitate screening genotypes and phenotypes (Agache & Akdis, 2019).

CYP genetic polymorphisms lead to variations in responses to medications among populations from different ethnicities (Ahmed et al., 2021; Alali et al., 2022; Dehbozorgi et al., 2018; Liao, Liu, Ai, Yu, & Li, 2018). For instance, the *CYP2D6**4 (*rs3892097*) variant is most commonly found in Europeans, indicating a higher frequency of the "poor metabolizer" phenotype within these people (Alali et al., 2022). This CYP enzyme metabolizes about 25% of the currently widely used medications, such as antiarrhythmics, antidepressants, antipsychotics, opioids, and beta-blockers (Alali et al., 2022). Moreover, in East Asian populations, the frequency of *CYP2C19* loss-of-function alleles is significantly higher than in individuals from other regions (Y.-W. Chen et al., 2022). This enzyme plays a crucial role in the metabolism of several medications, including proton pump inhibitors (e.g., omeprazole), anticonvulsants (such as phenytoin), and antiplatelet drugs (like clopidogrel) (Elbe et al., 2022). A study examined the impact of *CYP2C19* genetic variations on the pharmacologic effect of omeprazole in Iranian individuals with erosive reflux esophagitis (Zendehdel et al., 2010). The study found that *CYP2C19* genetic polymorphism influences omeprazole therapy, affecting clinical response and esophagitis endoscopic healing based on different genotypes (Zendehdel et al., 2010). Recent research indicates a link between *CYP2C19* polymorphisms, plasma levels of proton pump inhibitors, and the likelihood of adverse drug reactions (Ibrahim, Yusuff, Awaisu, & Elewa, 2025). Due to this concern, the Clinical Pharmacogenetics Implementation Consortium (CPIC) has recommended genotype-guided dosing for proton pump inhibitors. According to CPIC guidelines, individuals classified as intermediate or poor metabolizers face a greater risk of adverse effects. To mitigate this risk, dose reductions are advised for these patients (Ibrahim et al., 2025). Regarding phenytoin metabolism, *CYP2C19* and *CYP2C9* are crucial for this

biological process (Yaşar, 2018). CYP2C9 is a genetically polymorphic enzyme. *CYP2C9**2 and *3 variants are associated with reducing the metabolism of various medications (Yaşar, 2018). The *CYP2C9**2 and *3 single-nucleotide polymorphisms (SNPs) are prevalent particularly in Caucasian and Asian subjects, respectively (Y. Zhou, Nevosadová, Eliasson, & Lauschke, 2023). The CPIC guidelines offer a framework for tailoring phenytoin treatment based on *CYP2C9* genetic data to improve patient safety (Whirl-Carrillo et al., 2021). Conducting pharmacogenetic testing for *CYP2C9* variations prior to treatment could enhance the accuracy of phenytoin dosing and increase safety (Chang, Hung, Carleton, & Chung, 2020; Fohner et al., 2020). These SNPs influence the pharmacokinetics of phenytoin and could result in adverse drug reactions such as drug rash with eosinophilia and systemic symptom (DRESS) syndrome (Yaşar, 2018). Therefore, standard doses of medications could result in toxicities due to the raised serum levels of medications in the case of patients regarded as poor metabolizers (Ibrahim et al., 2025; Shubbar et al., 2024). Furthermore, some medications, like losartan or tramadol, are not effective as a pharmacologic treatment before their metabolism to active forms (Mahajna et al., 2024; Park, Song, Yee, Yoon, & Gwak, 2021). These medicines are called prodrugs. In case of poor metabolizers of these prodrugs, treatment failure could occur due to the reduced or no production of the active form of the medications (Mahajna et al., 2024; Park et al., 2021).

The activity of CYP plays a significant role in the variability of medication pharmacokinetics (Magliocco, Thomas, Desmeules, & Daali, 2019). Much research has been done to study the influence of CYP genetic variations on the pharmacokinetics of drugs (Gong et al., 2025; Nakajima, 2017). For example, the time needed to reach the appropriate therapeutic trough level of tacrolimus was

significantly longer for individuals classified as CYP3A extensive metabolizers than those classified as CYP3A poor metabolizers (Calabrese et al., 2018). In addition, clopidogrel requires activation by the CYP2C19 enzyme, which is genetically polymorphic (Pereira et al., 2024). Loss-of-function variants in *CYP2C19* can affect pharmacokinetics response; lead to reduced active metabolite levels, increased platelet aggregation, and a higher risk of ischemic events during clopidogrel therapy. Genetic testing for *CYP2C19* can identify affected patients, allowing for alternative treatment options (Pereira et al., 2024). On this point, genetic polymorphisms in metabolic enzymes such as CYP3A4 and CYP3A5 were associated with variations in the pharmacokinetics of statins (Maslub, Radwan, Daud, & Sha'aban, 2023).

Atorvastatin is regarded as one of the most frequently prescribed drugs and the most widely used statin globally (Adams, Tsang, & Wright, 2015; Maslub et al., 2023). It is currently recommended to manage dyslipidaemia and hypercholesterolaemia (Shawish, Bagheri, Musini, Adams, & Wright, 2021). However, it is associated with several adverse reactions, like nausea, nasopharyngitis, insomnia, urinary tract infections, elevation in hepatic enzymes, diarrhoea, dyspepsia, myalgia, and arthralgia (Maslub et al., 2023; Parke-Davis, 2009).

Both CYP3A4 and CYP3A5 enzymes are responsible for atorvastatin metabolism (Figure 1.1). Therefore, *CYP3A4* or *CYP3A5* genetic polymorphisms lead to interindividual differences in the metabolism mediated by the corresponding enzymes (Maslub et al., 2023). In light of these polymorphisms, Binbin Xia et al. study of 187 Chinese subjects showed that atorvastatin maximum plasma concentration (C_{max}) was significantly elevated (high atorvastatin exposure) in the

carriers of specific genes, including *CYP3A4*1B* (*rs2740574*) in addition to other genes involved in atorvastatin metabolism and transport in vivo. Moreover, one subject was terminated during the study due to atorvastatin intolerance (Xia et al., 2018). Likely, the *CYP3A4*22* variant is linked to a lower statin dosage required (D. Wang, Guo, Wrighton, Cooke, & Sadee, 2011b). Clinical research validated the relationship between *CYP3A4*22* and the pharmacokinetics of statins (Werk & Cascorbi, 2014). Despite some inconsistent data (Ragia et al., 2015), *CYP3A4*22* appears to be the most clinically significant common variation of *CYP3A4* (Werk & Cascorbi, 2014; Zanger & Schwab, 2013). Regarding the *CYP3A5* gene polymorphism, individuals who express *CYP3A5* are anticipated to have a greater metabolic capacity, which would likely lead to reduced bioavailability of atorvastatin (Zubiaur et al., 2021). Accordingly, *CYP3A5* non-expressers (*CYP3A5*3/*3* genotype carriers) were associated with an increased risk of experiencing myalgia and muscle damage in comparison to those with the **1/*3* genotype (Zubiaur et al., 2021). Within this context, *CYP3A4* and *CYP3A5* genetic variations result in differences in atorvastatin metabolism (Maslub et al., 2023).

Methylenetetrahydrofolate reductase (MTHFR) is a crucial enzyme involved in homocysteine (Hcy) metabolism (Zaremska, Ślusarczyk, & Wrzosek, 2024). MTHFR irreversibly catalyzes the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is needed for the remethylation of Hcy to methionine. Methionine is then converted to S-adenosylmethionine (SAM), a universal methyl donor that functions in several trans-methylation processes, including DNA methylation, proteins, lipids, and polyamines. This conversion is essential for regulating intracellular Hcy levels and maintaining appropriate SAM levels (Kucukhuseyin et al., 2013; Zaremska et al., 2024). Hyperhomocysteinemia

is one of the classical risk factors for CVDs in addition to hyperlipidemia, genetics, smoking, age, hypertension, diabetes mellitus, family history, and obesity (Kathiresan & Srivastava, 2012; Zaremska et al., 2024). Hence, MTHFR deficiency is frequently associated with increased plasma Hcy levels that elevate the risk of CVDs (Izmirli M., 2014; Zaremska et al., 2024).

The *MTHFR* genetic polymorphism was found to have a significant effect on atorvastatin pharmacokinetics in a pharmacogenetics Mexican pilot study (León-Cachón et al., 2016). Individuals who carry the variant allele for *MTHFR* (*rs1801133*) showed a reduced C_{max} and area under the curve (AUC) values, along with a higher apparent oral clearance (CL/F). This pharmacokinetic pattern indicates increased clearance activity and lower levels of atorvastatin in the system, which may lead to a less effective response to atorvastatin treatment (León-Cachón et al., 2016). This pilot study is the first to report an effect of the *MTHFR* (*rs1801133*) SNP on statin pharmacokinetics. However, the study did not provide a clear interpretation of the association between the *MTHFR* SNP and atorvastatin pharmacokinetics. It concluded that the mechanism by which the variant allele of *MTHFR* (*rs1801133*) enhances atorvastatin clearance, leading to a diminished drug response, remains to be clarified (León-Cachón et al., 2016).

The recent emphasis on personalized medication dosages underscores the importance of understanding genetic factors in pharmacotherapy (Principi, Petropulacos, & Esposito, 2023). Research indicates that genetic variations can account for up to 95% of the variability in individual responses to medications (Principi et al., 2023). Recent studies have highlighted the significant impact of pharmacogenetics on individual responses to atorvastatin therapy (Dagli-Hernandez

et al., 2022; Ruiz-Iruela et al., 2018). Consequently, the occurrence of polymorphisms in genes implicated in the metabolic pathway of atorvastatin may account for its pharmacokinetics variability (Eichelbaum, Ingelman-Sundberg, & Evans, 2006; Kim et al., 2022; Maslub, Daud, Radwan, Sha'aban, & Ibrahim, 2024; Maslub et al., 2023), given that their prevalence and effects vary between distinct ethnic groups (Hirschhorn & Daly, 2005; Kim et al., 2022; Maslub et al., 2024). Hence, pharmacogenomic studies seek to optimize the usage of pharmacologic treatments in clinical practice settings (Gong et al., 2025).




Figure 1.1 CYP3A4 mainly metabolizes atorvastatin through major pathways and minor pathways via CYP3A5 and CYP2D6. This figure was created using BioRender.com.

ATV = atorvastatin, CHO = cholesterol, CYP = cytochrome P450, MVA = mevalonate, SLCO = solute carrier organic anion 'superfamily of transporters'

1.2 Problem statement & Study rationale

In Egypt, 46% of overall deaths are related to CVDs (Mach et al., 2020; Taha et al., 2021). Dyslipidemia increases the risk of CVDs. Several studies showed that high blood cholesterol has been found in 37% of Egyptians (Farag et al., 2017; Reda, Abdel-Rehim, Etman, & Afifi, 2014; Taha et al., 2021). Statins are the first-line treatment for dyslipidemia. Responses to statin therapy show apparent interpersonal deviations in the expected lipid-lowering efficacy. Atorvastatin is an example; polymorphisms in genes responsible for metabolism, distribution, and uptake might substantially modulate therapeutic outcomes (Rosales et al., 2012). These variations in responses develop a significant clinical problem (Nakajima, 2017; Sarlis & Gourgiotis, 2005). Differences in the pharmacokinetics of statins were related to genetic mutations in metabolic enzymes such as CYP3A4 and CYP3A5 (Willrich et al., 2013). CYP3A4 metabolizes 45% to 60% of drugs presently recommended in clinical practice (Lv et al., 2018). CYP3A5 isoform is also regarded as the significant subfamily of the hepatic metabolic enzymes. CYP3A5 genetic polymorphism is linked to variations among people and ethnic groups in medication pharmacokinetics and therapeutic effects (Ang et al., 2018).

Atorvastatin is considered one of the most commonly recommended medications and the most extensively prescribed statin worldwide (Adams et al., 2015). The outcomes of association studies of CYP3A4 and CYP3A5 with response to atorvastatin were inconsistent. Some research has linked polymorphisms of these enzymes to positive clinical consequences after atorvastatin therapy, and some linked them to negative therapeutic outcomes (Kee, Chin, Kennedy, & Maggo, 2020). The issue is that genetic polymorphisms lead to differences in responses to drug therapy (Hauser et al., 2018). These dissimilar responses are significantly apparent among

different populations (Ahmed et al., 2021; Dehbozorgi et al., 2018; Liao et al., 2018). Moreover, the effects of genetic variations of *CYP3A4*1B* and *CYP3A5*3* on atorvastatin therapy were not previously studied among the Egyptian population.

CYP genetic polymorphisms lead to variations in response to medications among populations from different ethnicities. The efficacy and safety of medications could be modulated due to CYP polymorphisms (Ahmed et al., 2021; Dehbozorgi et al., 2018; Liao et al., 2018). Regarding *CYP3A4* genetic variations in diverse ethnicities, a study on Chilean subjects illustrated that the G allele of the variant *rs2740574* in the *CYP3A4* was linked to a better response to atorvastatin. This polymorphism resulted in a decrease in the metabolic activity of *CYP3A4* and an enhancement in atorvastatin efficacy (Rosales et al., 2012). A different study on Indian individuals has shown a dissimilar result. It demonstrated no significant association between the *rs2740574* variant and low values of low-density lipoprotein cholesterol (LDL-C) as a response to atorvastatin pharmacotherapy (Ahangari et al., 2020; Poduri et al., 2010). Moreover, the variant *CYP3A4*1B* (*rs2740574*) influenced statin intolerance (Melhem et al., 2021). In Dutch individuals, the G allele of this variant reduced the risk of atorvastatin's adverse effects due to its association with low plasma levels of atorvastatin (Becker et al., 2010; Kee et al., 2020). On the other hand, a study that recruited African Americans and Caucasians demonstrated that *CYP3A4*1B* (*rs2740574*) was not linked to atorvastatin therapy intolerance (Kee et al., 2020; Voora et al., 2009).

Concerning *CYP3A5* polymorphism in different ethnicities, a study involving Han Chinese subjects showed that *CYP3A5*3* genetic variation could result in inter-individual variations in response to atorvastatin treatment (Wei & Zhang, 2015).

However, a study on Chilean patients showed that the G and A alleles of the *rs776746* variant had no influence on response to atorvastatin therapy (Rosales et al., 2012). Moreover, a meta-analysis showed the effect of *CYP3A5*3* genetic variations on the risk of intolerance to statin therapy, including atorvastatin. Furthermore, it concluded that genotyping may help in identifying patients at risk for adverse drug reactions (Yee et al., 2021). However, the Han Chinese cases showed that the G allele of the *rs776746* variant was not linked to adverse effects (J. E. Liu et al., 2017).

More research in different ethnic populations is needed to confirm that the intron 6 SNP (*rs35599367*, *CYP3A4*22*) significantly influences *CYP3A4* expression and is a biomarker for predicting responsiveness to atorvastatin (D. Wang et al., 2011b). In addition, further studies are necessary to verify that the *MTHFR* (*rs1801133*) polymorphism is a predictive biomarker for responsiveness to atorvastatin (León-Cachón et al., 2016).

To the best of our knowledge, both alleles C and T of the variant *rs2740574* in the *CYP3A4* gene were not studied before in the Egyptian population. In addition, the effects of genetic polymorphisms of *CYP3A4* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A) and *MTHFR* (*rs1801133* G/A) on atorvastatin plasma concentration and its induced adverse effects were not previously studied among Egyptians.

Consequently, this study will assist a significant number of Egyptians suffering from hypercholesterolemia and are at high risk of CVDs complications by tailoring of atorvastatin treatment based on the patient's genotype. The findings would enhance the efficacy and reduce the risk of atorvastatin-induced adverse

effects and treatment costs. The findings of our study will be part of the efforts made by the Egyptian government through the tremendous national scientific project called "Egyptian Genome" (University, 2020; Wohlers et al., 2020).

1.3 Research Question(s)

1.3.1 What are the allele frequencies of *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A), and *MTHFR* (*rs1801133* G/A) among the study Egyptian population?

1.3.2 Would atorvastatin efficacy (serum lipid and lipoprotein levels) be affected by the genetic polymorphisms of these enzymes?

1.3.3 Would atorvastatin plasma levels be affected by the genetic polymorphisms of these enzymes?

1.3.4 Would atorvastatin safety (liver enzymes, TB, and CK levels) be affected by the genetic polymorphisms of these enzymes after atorvastatin four-week treatment?

1.3.5 Would the pharmacokinetics profile of atorvastatin be affected in carriers of the homozygous mutant genotypes of *CYP3A4*1B* (*rs2740574* C/T) and *CYP3A5*3* (*rs776746* T/C) SNPs? (The investigation will focus solely on the *CYP3A4*1B* (Al-Eitan, 2020) and *CYP3A5*3* (Mutawi et al., 2021) variants. Literature data suggest that these variants have a higher prevalence compared to *CYP3A4*22* (*rs35599367* G/A) (Ebid, Ismail, Lotfy, Mahmoud, & M, 2022) and *MTHFR* (*rs1801133* G/A) (El-Khawaga et al., 2024) SNPs in similar populations. Additionally, the study is constrained by the principal investigator's personal funding, which limited the exploration of the associations between other SNPs and atorvastatin pharmacokinetics.)

1.4 Research hypotheses

1.4.1 The allele frequencies of *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A), and *MTHFR* (*rs1801133* G/A) among the study Egyptian population would be similar to Caucasians.

1.4.2 The genetic polymorphisms of these enzymes affect serum lipid and lipoprotein levels (atorvastatin efficacy). The *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), and *CYP3A4*22* (*rs35599367* G/A) are associated with improving the lipid profile. However, the *MTHFR* (*rs1801133* G/A) is associated with worsening the lipid profile.

1.4.3 The genetic polymorphisms of these enzymes impact atorvastatin plasma levels. The *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), and *CYP3A4*22* (*rs35599367* G/A) are associated with high atorvastatin plasma levels. However, the *MTHFR* (*rs1801133* G/A) is associated with low atorvastatin plasma levels.

1.4.4 The genetic polymorphisms of these enzymes affect liver enzyme levels, TB, and CK levels after atorvastatin treatment. The *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), and *CYP3A4*22* (*rs35599367* G/A) are associated with high liver enzyme levels, TB, and CK levels. However, the *MTHFR* (*rs1801133* G/A) is associated with low liver enzyme levels, TB, and CK levels.

1.4.5 In carriers of the homozygous mutant genotypes of the *CYP3A4*1B* (*rs2740574* C/T) and *CYP3A5*3* (*rs776746* T/C) alleles, the pharmacokinetics profile of atorvastatin is affected.

1.5 Research aim and objectives

1.5.1 General

This research aims to investigate the association between *CYP3A4*, *CYP3A5*, or *MTHFR* polymorphisms and atorvastatin efficacy and safety in the Egyptian population.

To minimize potential confounding factors, strict eligibility criteria were applied. In order to better control for confounders, individuals taking medications that could interact with atorvastatin, including recent lipid-lowering agents and insulin therapy, were excluded. Participants with comorbidities such as uncontrolled hypothyroidism, poor liver function, or other significant clinical conditions,

including stroke, were also not included. Additionally, all individuals refrained from consuming alcohol both prior to and throughout the study. While some may have been smokers, they were required to abstain entirely from smoking throughout the research period. All subjects also avoided strenuous physical activity starting one week before the study and throughout its duration.

1.5.2 Specific

1.5.2(a) Objective 1

To determine the allele frequencies of *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A), and *MTHFR* (*rs1801133* G/A) alleles among the Egyptian study participants.

1.5.2(b) Objective 2

To determine the association between *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A), or *MTHFR* (*rs1801133* G/A) genetic polymorphisms and changes in serum lipid and lipoprotein levels after atorvastatin treatment among the Egyptian study participants.

1.5.2(c) Objective 3

To determine the relationships between atorvastatin plasma levels among the Egyptian study participants and the genetic polymorphisms of *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A) or *MTHFR* (*rs1801133* G/A).

1.5.2(d) Objective 4

To determine the association between *CYP3A4*1B* (*rs2740574* C/T), *CYP3A5*3* (*rs776746* T/C), *CYP3A4*22* (*rs35599367* G/A) or *MTHFR* (*rs1801133*

G/A) alleles and changes in liver enzymes, TB and CK levels after atorvastatin treatment among the Egyptian study participants.

1.5.2(e) Objective 5

To determine the pharmacokinetics profile of atorvastatin in carriers of the homozygous mutant genotypes of *CYP3A4*1B* (*rs2740574* C/T) and *CYP3A5*3* (*rs776746* T/C) SNPs.

CHAPTER 2

LITERATURE REVIEW

2.1 Genetic polymorphisms that affect atorvastatin response

Several genetic polymorphisms affect atorvastatin's response. Pharmacokinetic variation is a primary source of interpersonal dissimilarities in the pharmacologic effect and response of medications metabolized by the CYP3A pathway (Hohmann, Haefeli, & Mikus, 2016). CYP3A4 isoform metabolizes more clinically used medications than any other metabolic enzyme found in human beings (Werk & Cascorbi, 2014). Atorvastatin is metabolized to active metabolites by CYP3A4 (Zubiaur et al., 2021). Moreover, a previous study showed that CYP3A4 and CYP3A5 were responsible for 85% and 15% of atorvastatin metabolism, respectively (Figure 1.1). Inter-personal variations in CYP3A metabolic pathways are also pronounced, with 20- and 40-fold variability in metabolism. These differences may be associated with polymorphisms in *CYP3A4* or *CYP3A5* (Kitzmiller, Sullivan, Phelps, Wang, & Sadee, 2013). In the same context, atorvastatin is known to be a substrate of the organic anion transporter polypeptides (OATP1B1) and (OATP1B3), encoded by *SLCO1B1* and *SLCO1B3* genes, respectively. Consequently, genetic polymorphisms are linked to variations in atorvastatin efficacy and safety profile (Zubiaur et al., 2021). In addition to genetic variations in these transporters, The MTHFR enzyme, crucial for Hcy metabolism (Zaremska et al., 2024), has been studied for its potential impact on atorvastatin pharmacokinetics due to its polymorphism (León-Cachón et al., 2016), as shown in Table 2.1.

2.2 Worldwide allele frequencies of *CYP3A4*1B*, *CYP3A4*22*, *CYP3A5*3*, and *MTHFR* SNPs across ethnicities

The *CYP3A4*1B* (*rs2740574*) SNP is linked to decreased enzymatic activity (Rosales et al., 2012). *CYP3A4*1B* allele frequency varies among ethnicities (C.-e. Wang, Lu, Chang, Guo, & Qiao, 2018). The frequency of the *CYP3A4*1B* allele varies from 0 to 4% in Asian and European populations, and it can be as high as 82% in African populations (Q. Zhou et al., 2011).

The intronic SNP (*rs35599367*, *CYP3A4*22*) decreases *CYP3A4* mRNA and protein expression (D. Wang et al., 2011b). The frequency of the *CYP3A4*22* allele is 5.0% among Europeans, 2.6% in the mixed American population, and less than 1% in the Asian and African populations (van Eerden et al., 2023).

The *CYP3A5*3* SNP leads to a truncated malfunctioning protein in homozygous cases (nonexpressors) (Milane et al., 2021). The frequency of the *CYP3A5*3* allele differs notably across various populations. It is most common in Europeans (94%) and admixed Americans (80%) and least common in the African population (18%) (Galaviz-Hernández et al., 2020).

The *MTHFR rs1801133* variant interferes with the folate metabolic pathway by reducing the activity and thermostability of the *MTHFR* enzyme, thereby disrupting the methylation process (Chiu et al., 2023). The interference in folate metabolism is associated with higher plasma Hcy (Chiu et al., 2023). The *MTHFR* (*rs1801133*) allele was found to occur in 24-40% of Europeans, 40% of Koreans, and 26-37% of Japanese individuals (L. Zhao et al., 2022).

2.3 Influence of CYP3A polymorphisms on atorvastatin efficacy

2.3.1 Influence of *CYP3A4*1B* polymorphism

CYP3A4 is involved in the metabolism of the lipid-lowering agent atorvastatin. It has been demonstrated that CYP3A4 activity can vary up to 10-fold amongst carriers of genetic variants for this isoenzyme (Ahangari et al., 2020; Hirota, Fujita, & Ieiri, 2020; Lennernäs, 2003). This enzyme could predict the response to statin treatment and adverse effects (Ahangari et al., 2020). Research on the Chilean population showed that the G allele of the variant *rs2740574* in the *CYP3A4* was associated with a better response to atorvastatin. This genetic mutation is linked to a reduced CYP3A4 function, leading to an increased atorvastatin effect (Rosales et al., 2012).

Research on the Indian population has demonstrated a different finding (Kadam, Ashavaid, Ponde, & Rajani, 2016). Kadam et al. found that the wild genotype of the *rs2740574* variant was associated with low values of LDL-C in comparison to the mutant G-allele associated with higher values (Kadam et al., 2016). Another research on the Indian population has shown no significant relationship between the *rs2740574* variant and low values of LDL-C as a response to atorvastatin therapy (Ahangari et al., 2020; Poduri et al., 2010). The reasons behind these different findings could be related to genetic polymorphisms, which can have varying frequencies and effects across populations (Kim et al., 2022; Maslub et al., 2024). Additionally, study design and sample size are critical factors influencing the findings of genetic studies, particularly those focusing on SNPs (Bralić & Buljan, 2023; Politi, Roumeliotis, Tripepi, & Spoto, 2023).

2.3.2 Influence of *CYP3A4*22* polymorphism

Wang et al., 2011 genotyped seven polymorphisms in *CYP3A4/3A5* using gDNA from 273 individuals. Participants were part of the Coronary Artery Disease (CAD) Study at Ohio State University (D. Wang et al., 2011b). Patients using stable dosages (same dose for at least six months) of a hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (statins) for cholesterol management were chosen for this research (n=142; atorvastatin). Each patient's statin dose was adjusted to achieve established cholesterol control targets. Lipid levels were assessed at enrolment and after achieving a steady statin dosage. After joining the study, individuals did not take any other lipid-lowering medications. Intron 6 SNP (*rs35599367*, C>T) significantly impacts *CYP3A4* expression and might be a biomarker for predicting responsiveness to *CYP3A4*-metabolized medications. Carriers of the T allele required considerably lower statin dosages (0.2–0.6-fold, P = 0.019) than non-T carriers to achieve optimum lipid control in patients receiving stable doses of atorvastatin for lipid management (D. Wang et al., 2011b).

Ragia et al., 2015 examined the relationship between the *CYP3A4*22* allele and atorvastatin responsiveness. The trial comprised 207 Greek people with primary hypercholesterolemia who were treated with atorvastatin. TC and LDL-C were assessed at the beginning of therapy and six months afterwards. TaqMan test was used to study the *CYP3A4*22* allele. Eighteen people in the overall cohort group possessed the *CYP3A4*22* allele. The *CYP3A4*22* allele was not linked with an atorvastatin lipid-lowering response. Significant confounding or uncontrolled variables, such as polypharmacy and coexisting medical conditions, may obscure the effect of the *CYP3A4*22* allele on the lipid-lowering effect of atorvastatin; consequently, more population-based research is necessary (Ragia et al., 2015).

In a trial conducted in Athens, 105 unrelated children and adolescents with familial hypercholesterolemia (FH) were treated with atorvastatin at dosages from 10 to 40 mg (Drogari et al., 2014). Total cholesterol and LDL-C levels of these patients were evaluated at baseline and six months after therapy initiation. The study showed that *CYP3A4**22 genotype was not linked with lipid reductions in 105 children and adolescents treated with atorvastatin for familial hypercholesterolemia. However, more research in other groups is required to reproduce this finding (Drogari et al., 2014).

These differing findings may be attributed to genetic polymorphisms, which vary in frequency and impact among different populations (Kim et al., 2022; Maslub et al., 2024). Furthermore, the design of the study and the sample size play crucial roles in shaping the outcomes of genetic research (Bralić & Buljan, 2023; Politi et al., 2023).

2.3.3 Influence of *CYP3A53 polymorphism**

A study involving Han Chinese subjects demonstrated that *CYP3A5**3 genetic mutation could result in person-to-person variations in response to atorvastatin therapy. The study found that polymorphisms of P450 oxidoreductase *28 (POR*28) are linked to more significant increases in the effect on plasma lipids in carriers of *CYP3A5**3/*3 (Wei & Zhang, 2015). However, a research on Chilean patients showed that the G and A alleles of the *rs776746* variant did not affect response to atorvastatin treatment (Rosales et al., 2012).

The variation in findings could be explained by genetic polymorphisms, which differ in their frequency and effects across various populations (Kim et al., 2022; Maslub et al., 2024). Additionally, factors such as the study's design and the sample

size are essential in determining the results of genetic studies (Bralić & Buljan, 2023; Politi et al., 2023).

2.4 Influence of CYP3A polymorphisms on atorvastatin safety profile

2.4.1 Influence of CYP3A4*1B polymorphism

Furthermore, statin intolerance is influenced by the variant CYP3A4*1B (*rs2740574*) (Melhem et al., 2021). In the Dutch population, especially in females, the G allele of this variant was linked to a reduced risk of raised plasma concentrations of statins, which could lead to adverse drug reactions (Becker et al., 2010; Kee et al., 2020). However, an open-label randomized study illustrated that CYP3A4*1B (*rs2740574*) was not associated with atorvastatin therapy intolerance, elevation of CK, or muscle pain in Caucasian as well as African American subjects (Kee et al., 2020; Voora et al., 2009). Another case-control study showed a similar result in Caucasian subjects (Kee et al., 2020; Wilke, Moore, & Burmester, 2005). Consequently, the response to statin treatment significantly differs among populations (Rosales et al., 2012). The differences in research outcomes may be attributed to genetic polymorphisms, as their prevalence and impact vary among different populations (Kim et al., 2022; Maslub et al., 2024). Furthermore, elements like study design and sample size play a crucial role in shaping the findings of genetic research (Bralić & Buljan, 2023; Politi et al., 2023).

2.4.2 Influence of CYP3A4*22 polymorphism

Potential safety concerns have been raised by a study involving healthy Spanish individuals, which found that the CYP3A4*22 SNP was associated with increased atorvastatin exposure, as indicated by a high AUC. This suggested

decreased metabolic activity in carriers of this genetic variant. (Saiz-Rodríguez et al., 2020).

2.4.3 Influence of *CYP3A53 polymorphism**

Regarding intolerance to atorvastatin therapy, the level of serum CK was 25% higher in carriers of the genotype *CYP3A5**3/3 (non-expressors) than in other genotypes (Kee et al., 2020; Wilke et al., 2005). Furthermore, a meta-analysis illustrated the significant influence of *CYP3A5**3 genetic variations on the risk of adverse effects due to statin therapy, including atorvastatin. Moreover, it concluded that *CYP3A5* genotyping could help predict drug-induced toxicities (Yee et al., 2021). On the other hand, research on the Indian population (from south India) showed that the frequency of the genotype *CYP3A5**3/3 of the variant *rs776746* was higher in the cases who suffered myopathy. However, the study could not find any relation between the *CYP3A5* mutation and atorvastatin therapy (Kee et al., 2020; Ramakumari, Indumathi, Katkam, & Kutala, 2018). Another study involving Han Chinese patients demonstrated that the G allele of the *rs776746* variant was not associated with myotoxicity as an adverse effect of atorvastatin therapy (J. E. Liu et al., 2017). A case-control study demonstrated the same result in which indigenous American, sub-Saharan, East Asian, and European subjects were recruited (Frudakis et al., 2007; Kee et al., 2020). Variations in research results can be linked to genetic polymorphisms, as their frequency and effects differ across diverse populations (Kim et al., 2022; Maslub et al., 2024). Additionally, factors such as study methodology and the number of participants significantly influence the outcomes of genetic studies (Bralić & Buljan, 2023; Politi et al., 2023).

2.5 CYP3A4 polymorphism among Egyptians

Both alleles C and T of the variant *rs2740574* in the *CYP3A4* gene were not studied before in the Egyptian population. In April 2021, pharmacogenomic research was done at the pediatric hospital, Faculty of Medicine, Mansoura University, Mansoura Governorate, Egypt (Mutawi et al., 2021). The research has been conducted to investigate major allelic variants of certain CYPs. It has shown that the frequency of a different variant, *rs35599367*, in the gene *CYP3A4*22* was 2%. It is the first study illustrating the *CYP3A4*22* variant frequency in the Egyptian population (Mutawi et al., 2021). Furthermore, the frequency of an additional variant *rs4646437* in the *CYP3A4* gene was reported in another Egyptian study to be 20%. The study included 50 Egyptian patients after kidney transplantation at the Renal Transplantation Unit of Alexandria University Hospital, Alexandria Governorate, Egypt. The study was designated to demonstrate the influence of *CYP3A4* polymorphism on cyclosporine dosing in a group of renal transplant Egyptian recipients. The study showed that *CYP3A4 rs4646437C>T* had a significant impact on cyclosporine pharmacokinetics; the T carriers required higher cyclosporine dosing (Sharaki, Zeid, Moez, Zakaria, & Nassar, 2015).

2.6 CYP3A5*3 polymorphism among Egyptians

Concerning *CYP3A5*3* polymorphism among Egyptians, a study was held at the adult oncology department, National Cancer Institute, Cairo University, Giza Governorate, Egypt. It showed that the frequency of *CYP3A5*3* was higher (81.5%) in acute myeloid leukemia cases compared to controls (Abd El Wahab et al., 2017). Another Egyptian study, held at the Urology and Nephrology Center, Mansoura University Hospital, Mansoura, Egypt, reported an allele frequency of 85.53% for

*CYP3A5*3* among 76 renal transplantation recipients. This study was the first Egyptian research focusing on the personalization of tacrolimus doses in Egyptian cases according to the *CYP3A5* genotypes (Mendrinou et al., 2020). In addition, another study on Egyptian cases of chronic myeloid leukemia (CML) was conducted at the Hematology Department, Medical Research Institute, Alexandria University, Alexandria Governorate, Egypt. This research was designed to illustrate the role of *CYP3A5*3* polymorphism in determining the response to imatinib in 86 CML Egyptian cases. The result showed that the frequency of *CYP3A5*3* was 53% and 69% in seventy-eight (early chronic phase) cases and eight (accelerated phase) cases, respectively. *CYP3A5*3* genetic variation influenced imatinib efficacy and was linked to inferior outcomes (Bedewy & El-Maghraby, 2013).

Moreover, additional pharmacogenetic Egyptian research on 130 epileptic children was held at the Pediatrics Department, Menoufia University Hospital, Menoufia Governorate, Egypt. This research aimed to show the role of *CYP3A5*3* genetic variation in predicting resistance to antiepileptic medications in Egyptian epileptic pediatric cases. The prevalence of *CYP3A5*3* was 76.9% and 77.7% in epileptic (n=130) and control (n=65) participants, respectively. Children with epilepsy did not exhibit any pharmaco-resistance due to *CYP3A5*3* polymorphism (Abo El Fotoh, Abd El Naby, Habib, AA, & Kasemy, 2016). Due to the little data about pharmacogenes of significant clinical importance, 145 healthy, unrelated Egyptian children were also included in the research at Mansoura University Children's Hospital, Mansoura Governorate, Egypt. This pharmacogenomic research aimed to screen common genetic variants in certain CYPs, including *CYP3A5*, among the Egyptian population. The prevalence of the variant, 6986A>G (*rs776746*), in the gene *CYP3A5* was 86.2% (Mutawi et al., 2021). Consequently, recent evolution in